Market Cap 4.42B
Revenue (ttm) 383.48M
Net Income (ttm) -146.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -38.17%
Debt to Equity Ratio 0.00
Volume 4,834,300
Avg Vol 1,049,662
Day's Range N/A - N/A
Shares Out 57.35M
Stochastic %K 49%
Beta 0.76
Analysts Strong Sell
Price Target $119.50

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 367 9600
Fax: 949 367 9984
Address:
One Glaukos Way, Aliso Viejo, United States
ninergizer
ninergizer Oct. 30 at 9:19 PM
$INVA This is next, we hit $CRNX and $GKOS 25 % plus. Do your DD. PDUFA Date: Dec 15, 2025 Zoliflodacin — Oral antibiotic for gonorrhea FDA Likelihood: Very high (Priority Review, strong Phase 3, urgent CDC priority). Market Impact: Medium–large public health value, smaller direct commercial revenue. U.S. gonorrhea cases ~700k/year (CDC). New oral option = government/NGO contracts, global demand, less private pricing power. Potential: Blockbuster public health win, but sales may be constrained by stewardship and generic pricing.
0 · Reply
PrinceRobert
PrinceRobert Oct. 30 at 7:56 PM
$GKOS close my eyes! 👀
0 · Reply
PrinceRobert
PrinceRobert Oct. 30 at 6:14 PM
$GKOS Is time to pull back yet?
0 · Reply
Toptradersam
Toptradersam Oct. 30 at 6:00 PM
$CMBM $MTSR $GKOS $QCLS LFG!!! https://www.youtube.com/watch?v=Fy13hc2ICuo
0 · Reply
ZacksResearch
ZacksResearch Oct. 30 at 4:27 PM
$GKOS narrowed its Q3 loss — but why is it still a sell? 🤔 📈 Revenue up 38% YoY on a reported basis, beating estimates by 9.5% 🔍 Strong adoption of iDose TR supports innovation, and FDA approval of Epioxa marks a milestone 🔻 Yet, it's a Zacks Rank #4 (Sell) stock Understand the risks before investing in GKOS 👉 https://www.zacks.com/stock/news/2781810/gkos-stock-surges-following-q3-earnings-revenue-beat-guidance-raised?cid=sm-stocktwits-2-2781810-body-18509&ADID=SYND_STOCKTWITS_TWEET_2_2781810_BODY_18509
0 · Reply
ZacksResearch
ZacksResearch Oct. 30 at 3:27 PM
$GKOS just crushed Q3 — and the stock’s flying 🚀 Narrower loss, 38% revenue growth, and a raised 2025 outlook show iDose TR and Epioxa are driving serious momentum across Glaukos’ core franchises. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2781810/gkos-stock-surges-following-q3-earnings-revenue-beat-guidance-raised?cid=sm-stocktwits-2-2781810-teaser-18508&ADID=SYND_STOCKTWITS_TWEET_2_2781810_TEASER_18508
0 · Reply
topstockalerts
topstockalerts Oct. 30 at 2:35 PM
$GKOS strong watch for today..
0 · Reply
TaoistTrader
TaoistTrader Oct. 30 at 1:35 PM
$GKOS rang the bell up 25% on some of my shares. 🍀
0 · Reply
ShadowNest_16
ShadowNest_16 Oct. 30 at 1:29 PM
$GKOS 🏗️
0 · Reply
topstockalerts
topstockalerts Oct. 30 at 11:48 AM
Pre Market Top Gainers PT2 $VIVS $GH $ARBB $PFSA $GKOS
0 · Reply
Latest News on GKOS
Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 12:06 AM EDT - 22 hours ago

Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript


Glaukos Announces Third Quarter 2025 Financial Results

Oct 29, 2025, 4:05 PM EDT - 1 day ago

Glaukos Announces Third Quarter 2025 Financial Results


US FDA approves Glaukos' new eye therapy

Oct 20, 2025, 7:10 AM EDT - 10 days ago

US FDA approves Glaukos' new eye therapy


Glaukos Announces FDA Approval of Epioxa™

Oct 20, 2025, 7:00 AM EDT - 10 days ago

Glaukos Announces FDA Approval of Epioxa™


Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 5:15 AM EDT - 3 months ago

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript


Glaukos Announces Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 3 months ago

Glaukos Announces Second Quarter 2025 Financial Results


Glaukos Announces Participation in Upcoming Investor Conferences

May 13, 2025, 7:00 AM EDT - 6 months ago

Glaukos Announces Participation in Upcoming Investor Conferences


Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 10:05 PM EDT - 6 months ago

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript


Glaukos Announces First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 6 months ago

Glaukos Announces First Quarter 2025 Financial Results


Glaukos Announces the Release of its 2024 Sustainability Report

Apr 16, 2025, 7:00 AM EDT - 7 months ago

Glaukos Announces the Release of its 2024 Sustainability Report


Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 24, 2025, 7:00 AM EST - 8 months ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™


Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Feb 21, 2025, 4:29 AM EST - 8 months ago

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript


Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 23, 2024, 7:00 AM EST - 11 months ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™


Glaukos: Still Bullish, But Embedded Expectations Are Now High

Dec 21, 2024, 7:04 AM EST - 11 months ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High


Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:03 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript


Glaukos Announces Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Third Quarter 2024 Financial Results


Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 8:57 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript


Glaukos Announces Second Quarter 2024 Financial Results

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Second Quarter 2024 Financial Results


Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

May 1, 2024, 8:42 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript


Glaukos Announces First Quarter 2024 Financial Results

May 1, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces First Quarter 2024 Financial Results


ninergizer
ninergizer Oct. 30 at 9:19 PM
$INVA This is next, we hit $CRNX and $GKOS 25 % plus. Do your DD. PDUFA Date: Dec 15, 2025 Zoliflodacin — Oral antibiotic for gonorrhea FDA Likelihood: Very high (Priority Review, strong Phase 3, urgent CDC priority). Market Impact: Medium–large public health value, smaller direct commercial revenue. U.S. gonorrhea cases ~700k/year (CDC). New oral option = government/NGO contracts, global demand, less private pricing power. Potential: Blockbuster public health win, but sales may be constrained by stewardship and generic pricing.
0 · Reply
PrinceRobert
PrinceRobert Oct. 30 at 7:56 PM
$GKOS close my eyes! 👀
0 · Reply
PrinceRobert
PrinceRobert Oct. 30 at 6:14 PM
$GKOS Is time to pull back yet?
0 · Reply
Toptradersam
Toptradersam Oct. 30 at 6:00 PM
$CMBM $MTSR $GKOS $QCLS LFG!!! https://www.youtube.com/watch?v=Fy13hc2ICuo
0 · Reply
ZacksResearch
ZacksResearch Oct. 30 at 4:27 PM
$GKOS narrowed its Q3 loss — but why is it still a sell? 🤔 📈 Revenue up 38% YoY on a reported basis, beating estimates by 9.5% 🔍 Strong adoption of iDose TR supports innovation, and FDA approval of Epioxa marks a milestone 🔻 Yet, it's a Zacks Rank #4 (Sell) stock Understand the risks before investing in GKOS 👉 https://www.zacks.com/stock/news/2781810/gkos-stock-surges-following-q3-earnings-revenue-beat-guidance-raised?cid=sm-stocktwits-2-2781810-body-18509&ADID=SYND_STOCKTWITS_TWEET_2_2781810_BODY_18509
0 · Reply
ZacksResearch
ZacksResearch Oct. 30 at 3:27 PM
$GKOS just crushed Q3 — and the stock’s flying 🚀 Narrower loss, 38% revenue growth, and a raised 2025 outlook show iDose TR and Epioxa are driving serious momentum across Glaukos’ core franchises. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2781810/gkos-stock-surges-following-q3-earnings-revenue-beat-guidance-raised?cid=sm-stocktwits-2-2781810-teaser-18508&ADID=SYND_STOCKTWITS_TWEET_2_2781810_TEASER_18508
0 · Reply
topstockalerts
topstockalerts Oct. 30 at 2:35 PM
$GKOS strong watch for today..
0 · Reply
TaoistTrader
TaoistTrader Oct. 30 at 1:35 PM
$GKOS rang the bell up 25% on some of my shares. 🍀
0 · Reply
ShadowNest_16
ShadowNest_16 Oct. 30 at 1:29 PM
$GKOS 🏗️
0 · Reply
topstockalerts
topstockalerts Oct. 30 at 11:48 AM
Pre Market Top Gainers PT2 $VIVS $GH $ARBB $PFSA $GKOS
0 · Reply
healthcareguru
healthcareguru Oct. 30 at 11:16 AM
$GKOS short it here, fade all day…next catalyst is November 12th Medicare CAC meeting where iDose could get its TAM crushed. 👎
0 · Reply
erevnon
erevnon Oct. 30 at 11:11 AM
BTIG maintains Glaukos $GKOS at Buy and raises the price target from $104 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
topstockalerts
topstockalerts Oct. 30 at 11:01 AM
Pre Market Top Gainers PT2 $GH $TECX $GKOS $ARBB $MTSR
0 · Reply
PaulLaurent
PaulLaurent Oct. 30 at 6:01 AM
🚀📈 Top Gainers 📈🚀AH $GLE $GKOS $GH $NMRA $EBS
2 · Reply
StocktwitsNews
StocktwitsNews Oct. 30 at 3:24 AM
Why Glaukos Stock Jumped Over 20% After-Hours Today $GKOS https://stocktwits.com/news/equity/markets/why-glaukos-stock-jumped-over-20-after-hours-today/cLGFLwpR3DX
0 · Reply
erkdg
erkdg Oct. 30 at 1:58 AM
$GKOS Hidden gem! I hope it finally gets the attention it deserves.
0 · Reply
theflynews
theflynews Oct. 30 at 12:06 AM
Closing Bell Movers: Meta sinks, Alphabet jumps after earnings - $GKOS - https://thefly.com/permalinks/entry.php/GKOSid4224776?1761782558C
0 · Reply
TaoistTrader
TaoistTrader Oct. 29 at 11:04 PM
$GKOS today $HIMS Next week
0 · Reply
TaoistTrader
TaoistTrader Oct. 29 at 11:03 PM
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Oct. 29 at 10:52 PM
$GKOS Q3 '25 Earnings Results & Recap Glaukos reported record Q3 revenue of $133.5M, exceeding estimates, and raised 2025 revenue guidance to $490M-$495M, while also introducing a preliminary 2026 revenue guidance range of $600M-$620M.
0 · Reply
TaoistTrader
TaoistTrader Oct. 29 at 9:56 PM
$GKOS looking good, and nobody is here 😀
0 · Reply
DonCorleone77
DonCorleone77 Oct. 29 at 8:21 PM
$GKOS Glaukos reports Q3 EPS (16c), consensus (26c) -- Q3 revenue $133.5M, consensus $122.6M. -- Sees FY25 revenue $490M-$495M, consensus $484.6M
0 · Reply